Friday 6 November 2026 Export ABT’s income statement to Excel — free account

Abbott Laboratories

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.

Revenue: +14.5%
EPS: −43.6%
Free cash flow: +28.9%
Total debt: +142.7%

Quarter to September 2026, against a year earlier

110.32 3.28 −2.89%

Follow ABT

Alert me

Market cap: $196.6B
P/E: 42.3×
Fwd P/E: 35.1×
Dividend yield: 2.22%
F-score: 5/9
Altman Z: 5.61
Beneish M: −2.50
Dividend safety: 62/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Abbott Laboratories (ABT) revenue by segment, product and region

	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q1 FY2023
Medical Devices	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Diagnostic Products	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Nutritional Products	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Established Pharmaceuticals	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other Segments	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Cardiovascular And Neuromodulation Products	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Proprietary Pharmaceutical Products	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Unallocated Amount to Segment [Member] (Deprecated 2013-01-31)	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Reportable Segment [Member] (Deprecated 2013-01-31)	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Abbott Laboratories (ABT) revenue by segment, product and region

Stockrow Weekly